Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study

BACKGROUND: Tivozanib is a selective inhibitor of vascular endothelial growth factor receptors 1, 2 and 3 tyrosine kinases. This open-label, crossover clinical study (AV-951–09-902) provided access to tivozanib for patients who progressed on sorafenib in TIVO-1, comparing tivozanib with sorafenib in...

Descripción completa

Detalles Bibliográficos
Autores principales: Molina, Ana M., Hutson, Thomas E., Nosov, Dmitry, Tomczak, Piotr, Lipatov, Oleg, Sternberg, Cora N., Motzer, Robert, Eisen, Tim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6774240/
https://www.ncbi.nlm.nih.gov/pubmed/29547835
http://dx.doi.org/10.1016/j.ejca.2018.02.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6774240/
https://www.ncbi.nlm.nih.gov/pubmed/29547835
http://dx.doi.org/10.1016/j.ejca.2018.02.009

Ejemplares similares